Dipropanoylmorphine
A semi-synthetic opioid derived from morphine
| Dipropanoylmorphine | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 8002-20-2 |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Dipropanoylmorphine is a semi-synthetic opioid derived from morphine. It is an ester of morphine, specifically the 3,6-dipropionate ester. This compound is part of a class of drugs known as opioid analgesics, which are used for their pain-relieving properties.
Chemical Structure and Properties

Dipropanoylmorphine is chemically similar to morphine, with the addition of two propionyl groups at the 3 and 6 positions of the morphine molecule. This modification alters its pharmacokinetic properties, potentially affecting its potency, duration of action, and solubility compared to morphine.
Pharmacology
Dipropanoylmorphine acts on the opioid receptors in the central nervous system, primarily the mu-opioid receptor. This interaction leads to the inhibition of neurotransmitter release, resulting in analgesia, sedation, and euphoria. Like other opioids, it can also cause respiratory depression, constipation, and physical dependence.
Medical Use
While dipropanoylmorphine has been studied for its analgesic properties, it is not commonly used in clinical practice. The development of more effective and safer opioid analgesics has limited its use. However, it remains of interest in research settings for understanding the structure-activity relationships of opioid compounds.
Synthesis
The synthesis of dipropanoylmorphine involves the esterification of morphine with propionic anhydride. This chemical reaction results in the formation of the dipropionate ester, which is dipropanoylmorphine. The process requires careful control of reaction conditions to ensure the desired product is obtained.
Legal Status
Dipropanoylmorphine is classified as a controlled substance in many jurisdictions due to its potential for abuse and addiction. Its legal status is similar to that of other opioids, and it is subject to strict regulations regarding its manufacture, distribution, and use.
Related pages
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian